Canadian pharmaceutical company Bausch Health and generics maker Teva have resolved their dispute over Apriso (mesalazine), a drug used to treat ulcerative colitis and Crohn's disease.
Biopharmaceutical company Alkermes has entered into a settlement and licence agreement with generic maker Amneal Pharmaceuticals to resolve an inter partes review.
The state of California has secured a $69 million settlement with Teva, which allegedly entered into collusive pay-for-delay agreements with generic competitors.
Pfizer is to merge its off-patent drug business Upjohn with Mylan, in a deal that will see Pfizer shareholders own 57% of the new company.
US biotech company Celgene has agreed to pay a $55 million settlement after it was accused of illegally maintaining a monopoly over the market for its cancer treatments.
The US Food and Drug Administration last week approved nine applications for the first generic versions of Pfizer’s Lyrica.
Ireland-headquartered Endo Pharmaceuticals agreed to pay $2.3 million to 18 states late last week, settling allegations that the drugmaker paid a competitor to keep a generic version of pain relief drug Lidoderm off the market.
Johnson & Johnson has warned that strong competition from generic drugs could impact the company’s figures for the rest of the year.
India’s Delhi High Court has dismissed a petition for an injunction by German pharma company Bayer against an Indian competitor.
The US Court of Appeals for the Federal Circuit has upheld an earlier ruling that Indivior cannot stop two competitors from making a generic version of one of its drugs.